Potential of IDH mutations as immunotherapeutic targets in gliomas: a review and meta-analysis

References

• Ostrom QT, Patil N, Cioffi G, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017. Neuro Oncol. 2020 Oct;22(12 Suppl 2):iv1–iv96.
   PubMed Web of Science ®Google Scholar
• O’Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol. 2019 Mar;16(3):151–167.
   PubMed Web of Science ®Google Scholar
• Kane JR, Zhao J, Tsujiuchi T, et al. CD8(+) T-cell-mediated immunoediting influences genomic evolution and immune evasion in murine gliomas. Clin Cancer Res. 2020 Aug 15;26(16):4390–4401.
   PubMed Web of Science ®Google Scholar
• Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97–109.
   PubMed Web of Science ®Google Scholar
• Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016 Jun;131(6):803–820.
   PubMed Web of Science ®Google Scholar
• Reifenberger G, Wirsching HG, Knobbe-Thomsen CB, et al. Advances in the molecular genetics of gliomas - implications for classification and therapy. Nat Rev Clin Oncol. 2017 Jul;14(7):434–452.
   PubMed Web of Science ®Google Scholar
• Masui K, Mischel PS, Reifenberger G. Molecular classification of gliomas. Handb Clin Neurol. 2016;134:97–120.
   PubMedGoogle Scholar
• Wesseling P, Capper D. WHO 2016 classification of gliomas. Neuropathol Appl Neurobiol. 2018 Feb;44(2):139–150.
   PubMed Web of Science ®Google Scholar
• Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008 Sep 26;321(5897):1807–1812.
   PubMed Web of Science ®Google Scholar
• Brennan CW, Verhaak RG, McKenna A, et al. The somatic genomic landscape of glioblastoma. Cell. 2013 Oct 10;155(2):462–477.
   PubMed Web of Science ®Google Scholar
• Ludwig K, Kornblum HI. Molecular markers in glioma. J Neurooncol. 2017 Sep;134(3):505–512.
   PubMed Web of Science ®Google Scholar
• Koh HJ, Lee SM, Son BG, et al. Cytosolic NADP+-dependent isocitrate dehydrogenase plays a key role in lipid metabolism. J Biol Chem. 2004 Sep 17;279(38):39968–39974.
   PubMed Web of Science ®Google Scholar
• Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009 Dec 10;462(7274):739–744.
   PubMed Web of Science ®Google Scholar
• Chowdhury R, Yeoh KK, Tian YM, et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep. 2011 May;12(5):463–469.
   PubMed Web of Science ®Google Scholar
• Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011 Jan 18;19(1):17–30.
   PubMed Web of Science ®Google Scholar
• Huang LE. Friend or foe-IDH1 mutations in glioma 10 years on. Carcinogenesis. 2019 Nov25;40(11):1299–1307.
   PubMed Web of Science ®Google Scholar
• Paschka P, Schlenk RF, Gaidzik HM VI, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol. 2010 Aug 1;28(22):3636–3643.
   PubMed Web of Science ®Google Scholar
• Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010 May 18;17(5):510–522.
   PubMed Web of Science ®Google Scholar
• Wang JH, Chen WL, Li JM, et al. Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China. Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):17017–17022.
   PubMed Web of Science ®Google Scholar
• Montalban-Bravo G, DiNardo CD. The role of IDH mutations in acute myeloid leukemia. Future Oncol. 2018 Apr;14(10):979–993.
   PubMed Web of Science ®Google Scholar
• Natsumeda M, Igarashi H, Nomura T, et al. Accumulation of 2-hydroxyglutarate in gliomas correlates with survival: a study by 3.0-tesla magnetic resonance spectroscopy. Acta Neuropathol Commun. 2014 Nov7;2(1):158.
   PubMedGoogle Scholar
• Johnson BE, Mazor T, Hong C, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 2014 Jan 10;343(6167):189–193.
   PubMed Web of Science ®Google Scholar
• Núñez FJ, Mendez FM, Kadiyala P, et al. IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response. Sci Transl Med. 2019 Feb 13;11(479). DOI:https://doi.org/10.1126/scitranslmed.aaq1427.
   Google Scholar
• Gilbert MR, Liu Y, Neltner J, et al. Autophagy and oxidative stress in gliomas with IDH1 mutations. Acta Neuropathol. 2014 Feb;127(2):221–233.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Pusch S, Innes J, et al. Mutant IDH sensitizes gliomas to endoplasmic reticulum stress and triggers apoptosis via miR-183-mediated inhibition of semaphorin 3E. Cancer Res. 2019 Oct 1;79(19):4994–5007.
   PubMed Web of Science ®Google Scholar
• Weenink B, Draaisma K, Ooi HZ, et al. Low-grade glioma harbors few CD8 T cells, which is accompanied by decreased expression of chemo-attractants, not immunogenic antigens. Sci Rep. 2019 Oct 10;9(1):14643.
   PubMedGoogle Scholar
• Amankulor NM, Kim Y, Arora S, et al. Mutant IDH1 regulates the tumor-associated immune system in gliomas. Genes Dev. 2017 Apr 15;31(8):774–786.
   PubMed Web of Science ®Google Scholar
• Berghoff AS, Kiesel B, Widhalm G, et al. Correlation of immune phenotype with IDH mutation in diffuse glioma. Neuro Oncol. 2017 Oct 19;19(11):1460–1468.
   PubMed Web of Science ®Google Scholar
• Kohanbash G, Carrera DA, Shrivastav S, et al. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. J Clin Invest. 2017 Apr 3;127(4):1425–1437.
   PubMed Web of Science ®Google Scholar
• Kadiyala P, Carney SV, Gauss JC, et al. Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice. J Clin Invest. 2021 Feb 15;131(4). DOI:https://doi.org/10.1172/JCI139542.
   Google Scholar
• Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021 Aug 2;23(8):1231–1251.
   PubMed Web of Science ®Google Scholar
• Louis DN, Perry A, Burger P, et al. International society of neuropathology-haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathology (Zurich, Switzerland). 2014;24(5):429–435.
   PubMed Web of Science ®Google Scholar
• Ceccarelli M, Barthel FP, Malta TM, et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell. 2016 Jan 28;164(3):550–563.
   PubMed Web of Science ®Google Scholar
• Brat DJ, Verhaak RG, Aldape KD, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015 Jun 25;372(26):2481–2498.
   PubMed Web of Science ®Google Scholar
• Núñez FJ, Mendez FM, Kadiyala P, et al. IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response. Sci Transl Med. 2019;11(479):eaaq1427.
   PubMed Web of Science ®Google Scholar
• Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021 Aug 2;23(8):1231–1251.
   PubMed Web of Science ®Google Scholar
• Yoshihara K, Shahmoradgoli M, Martínez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4(1):2612.
   PubMed Web of Science ®Google Scholar
• Asad AS, Nicola Candia AJ, Gonzalez N, et al. The role of the prolactin receptor pathway in the pathogenesis of glioblastoma: what do we know so far? Expert Opin Ther Targets. 2020 Sep;29:1–13.
   Google Scholar
• Choi BD, Curry WT. IDH mutational status and the immune system in gliomas: a tale of two tumors? Transl Cancer Res. 2017 Oct;6(Suppl 7):S1253–s56.
   PubMedGoogle Scholar
• Lin W, Qiu X, Sun P, et al. Association of IDH mutation and 1p19q co-deletion with tumor immune microenvironment in lower-grade glioma. Mol Ther Oncolytics. 2021 Jun 25;21:288–302.
   PubMed Web of Science ®Google Scholar
• Goldman MJ, Craft B, Hastie M, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020 Jun 1;38(6):675–678.
   PubMed Web of Science ®Google Scholar
• Asad AS, Nicola Candia AJ, Gonzalez N, et al. Prolactin and its receptor as therapeutic targets in glioblastoma multiforme. Sci Rep. 2019 Dec 20;9(1):19578.
   PubMedGoogle Scholar
• Mu L, Long Y, Yang C, et al. The IDH1 mutation-induced oncometabolite, 2-hydroxyglutarate, may affect DNA methylation and expression of PD-L1 in gliomas. Front Mol Neurosci. 2018;11:82.
   PubMed Web of Science ®Google Scholar
• Röver LK, Gevensleben H, Dietrich J, et al. Promoter methylation is a prognostic factor in patients with diffuse lower-grade gliomas harboring isocitrate dehydrogenase mutations. EBioMedicine. 2018;28:97–104.
   PubMed Web of Science ®Google Scholar
• July J, Patricia D, Gunawan PY, et al. Clinicopathological associations and prognostic values of IDH1 gene mutation, MGMT gene promoter methylation, and PD-L1 expressions in high-grade glioma treated with standard treatment. Pan Afr Med J. 2020;36:309.
   PubMed Web of Science ®Google Scholar
• Richardson LG, Nieman LT, Stemmer-Rachamimov AO, et al. IDH-mutant gliomas harbor fewer regulatory T cells in humans and mice. OncoImmunology. 2020 Jan 1;9(1):1806662.
   PubMed Web of Science ®Google Scholar
• Klumper N, Ralser DJ, Bawden EG, et al. LAG3 (LAG-3, CD223) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma. J Immunother Cancer. 2020 Mar;8(1):e000552. doi:https://doi.org/10.1136/jitc-2020-000552.
   PubMed Web of Science ®Google Scholar
• Harris-Bookman S, Mathios D, Martin AM, et al. Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma. Int J Cancer. 2018 Dec 15;143(12):3201–3208.
   PubMed Web of Science ®Google Scholar
• Mair MJ, Kiesel B, Feldmann K, et al. LAG-3 expression in the inflammatory microenvironment of glioma. J Neurooncol. 2021 May;152(3):533–539.
   PubMed Web of Science ®Google Scholar
• Luoto S, Hermelo I, Vuorinen EM, et al. Computational characterization of suppressive immune microenvironments in glioblastoma. Cancer Res. 2018 Oct 1;78(19):5574–5585.
   PubMed Web of Science ®Google Scholar
• Plant AS, Koyama S, Sinai C, et al. Immunophenotyping of pediatric brain tumors: correlating immune infiltrate with histology, mutational load, and survival and assessing clonal T cell response. J Neurooncol. 2018 Apr;137(2):269–278.
   PubMed Web of Science ®Google Scholar
• Poon CC, Gordon PMK, Liu K, et al. Differential microglia and macrophage profiles in human IDH-mutant and -wild type glioblastoma. Oncotarget. 2019 May 3;10(33):3129–3143.
   PubMedGoogle Scholar
• Alghamri MS, McClellan BL, Avvari RP, et al. G-CSF secreted by mutant IDH1 glioma stem cells abolishes myeloid cell immunosuppression and enhances the efficacy of immunotherapy. Sci Adv. 2021 Oct;7(40):eabh3243.
   PubMed Web of Science ®Google Scholar
• Zhang X, Rao A, Sette P, et al. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression. Neuro Oncol. 2016 Oct;18(10):1402–1412.
   PubMed Web of Science ®Google Scholar
• Melaiu O, Chierici M, Lucarini V, et al. Cellular and gene signatures of tumor-infiltrating dendritic cells and natural-killer cells predict prognosis of neuroblastoma. Nat Commun. 2020 Nov25;11(1):5992.
   PubMed Web of Science ®Google Scholar
• Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013 Oct 17;39(4):782–795.
   PubMed Web of Science ®Google Scholar
• Ren F, Zhao Q, Huang L, et al. The R132H mutation in IDH1 promotes the recruitment of NK cells through CX3CL1/CX3CR1 chemotaxis and is correlated with a better prognosis in gliomas. Immunol Cell Biol. 2019 May;97(5):457–469.
   PubMed Web of Science ®Google Scholar
• Castriconi R, Daga A, Dondero A, et al. NK cells recognize and kill human glioblastoma cells with stem cell-like properties. J Immunol. 2009 Mar 15;182(6):3530–3539.
   PubMed Web of Science ®Google Scholar
• Mostafa H, Pala A, Högel J, et al. Immune phenotypes predict survival in patients with glioblastoma multiforme. J Hematol Oncol. 2016 Sep 1;9(1):77.
   PubMedGoogle Scholar
• Chimal-Ramírez GK, Espinoza-Sánchez NA, Fuentes-Pananá EM. Protumor activities of the immune response: insights in the mechanisms of immunological shift, oncotraining, and oncopromotion. J Oncol. 2013 Mar 14;2013:835956.
   PubMedGoogle Scholar
• Cheng W, Ren X, Zhang C, et al. Bioinformatic profiling identifies an immune-related risk signature for glioblastoma. Neurology. 2016 Jun 14;86(24):2226–2234.
   PubMed Web of Science ®Google Scholar
• Marinari E, Allard M, Gustave R, et al. Inflammation and lymphocyte infiltration are associated with shorter survival in patients with high-grade glioma. Oncoimmunology. 2020 Jun 21;9(1):1779990.
   PubMed Web of Science ®Google Scholar
• Kaminska B, Czapski B, Guzik R, et al. Consequences of IDH1/2 mutations in gliomas and an assessment of inhibitors targeting mutated IDH proteins. Molecules ( Basel, Switzerland). 2019 Mar 9;24(5):968.
   PubMed Web of Science ®Google Scholar
• Golub D, Iyengar N, Dogra S, et al. Mutant isocitrate dehydrogenase inhibitors as targeted cancer therapeutics. Front Oncol. 2019 May 17;9(417). DOI:https://doi.org/10.3389/fonc.2019.00417.
   Google Scholar
• Popovici-Muller J, Lemieux RM, Artin E, et al. Discovery of AG-120 (Ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers. ACS Med Chem Lett. 2018 Apr 12;9(4):300–305.
   PubMed Web of Science ®Google Scholar
• Mellinghoff IK, Penas-Prado M, Peters KB, et al. Vorasidenib, a dual inhibitor of mutant IDH1/2, in recurrent or progressive glioma; results of a first-in-human phase I trial. Clin Cancer Res. 2021;27(16):4491–4499.
   PubMed Web of Science ®Google Scholar
• Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002 May 15;20(10):2429–2440.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007 Jan 1;109(1):52–57.
   PubMed Web of Science ®Google Scholar
• Emadi A, Faramand R, Carter-Cooper B, et al. Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia. Am J Hematol. 2015 May;90(5):E77–9.
   PubMed Web of Science ®Google Scholar
• Borodovsky A, Salmasi V, Turcan S, et al. 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. Oncotarget. 2013 Oct;4(10):1737–1747.
   PubMedGoogle Scholar
• Turcan S, Fabius AW, Borodovsky A, et al. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT inhibitor decitabine. Oncotarget. 2013 Oct;4(10):1729–1736.
   PubMed Web of Science ®Google Scholar
• Yamashita AS, Da Costa Rosa M, Borodovsky A, et al. Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide. Neuro Oncol. 2019 Feb 14;21(2):189–200.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Nobusawa S, Kleihues P, et al. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 2009 Apr;174(4):1149–1153.
   PubMed Web of Science ®Google Scholar
• Schumacher T, Bunse L, Pusch S, et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature. 2014 Aug 1;512(7514):324–327.
   PubMed Web of Science ®Google Scholar
• Pellegatta S, Valletta L, Corbetta C, et al. Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma. Acta Neuropathol Commun. 2015 Jan 21;3(1):4.
   PubMed Web of Science ®Google Scholar
• Scheetz L, Kadiyala P, Sun X, et al. Synthetic high-density lipoprotein nanodiscs for personalized immunotherapy against gliomas. Clin Cancer Res. 2020 Aug 15;26(16):4369–4380.
   PubMed Web of Science ®Google Scholar
• Platten M, Bunse L, Wick A, et al. A vaccine targeting mutant IDH1 in newly diagnosed glioma. Nature. 2021 Apr;592(7854):463–468.
   PubMed Web of Science ®Google Scholar
• Reardon DA, Weller M. Vaccination for IDH-mutant tumors: a novel therapeutic approach applied to glioma. Med. 2021 May 14;2(5):450–452.
   Google Scholar
• Salas-Benito D, Perez-Gracia JL, Ponz-Sarvise M, et al. Paradigms on Immunotherapy combinations with chemotherapy. Cancer Discov. 2021 Jun;11(6):1353–1367.
   PubMed Web of Science ®Google Scholar
• Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res. 2015 May;3(5):436–443.
   PubMed Web of Science ®Google Scholar
• Yang P, Zhang W, Wang Y, et al. IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry. Oncotarget. 2015 Dec 1;6(38):40896–40906.
   PubMedGoogle Scholar
• Bhavya B, Anand CR, Madhusoodanan UK, et al. To be WILD OR MUTANT: ROLE OF ISOCITRATE DEHYDROGENASE 1 (IDH1) and 2-hydroxy glutarate (2-HG) in gliomagenesis and treatment outcome in glioma. Cell Mol Neurobiol. 2020 Jan;40(1):53–63.
   PubMed Web of Science ®Google Scholar
• Wang J, Cazzato E, Ladewig E, et al. Clonal evolution of glioblastoma under therapy. Nat Genet. 2016 Jul 1;48(7):768–776.
   PubMed Web of Science ®Google Scholar
• Butler M, Pongor L, Su YT, et al. MGMT status as a clinical biomarker in glioblastoma. Trends Cancer. 2020 May;6(5):380–391.
   PubMed Web of Science ®Google Scholar
• Cejalvo T, Gargini R, Segura-Collar B, et al. Immune profiling of gliomas reveals a connection with IDH1/2 mutations, tau function and the vascular phenotype. Cancers (Basel). 2020 Nov 2;12(11):3230.
   Web of Science ®Google Scholar
• Unruh D, Zewde M, Buss A, et al. Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers. Sci Rep. 2019 Jun 20;9(1):8946.
   PubMedGoogle Scholar
• Weller M, van Den Bent M, Preusser M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021 Mar 1;18(3):170–186.
   PubMed Web of Science ®Google Scholar
• Zhang L, Sorensen MD, Kristensen BW, et al. D-2-Hydroxyglutarate Is an Intercellular mediator in IDH-mutant gliomas inhibiting complement and T cells. Clin Cancer Res. 2018 Nov1;24(21):3230–3291.
   Web of Science ®Google Scholar
• Zhai L, Ladomersky E, Lauing KL, et al. Infiltrating T cells increase IDO1 expression in glioblastoma and contribute to decreased patient survival. Clin Cancer Res. 2017 Nov1;23(21):6650–6660.
   PubMed Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012 May;2(5):401–404.
   PubMed Web of Science ®Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013 Apr 2;6(269):l1.
   Web of Science ®Google Scholar